Amicus Therapeutics, Inc. (NASDAQ: FOLD) reported Q4 EPS of ($0.25), $0.12 better than the analyst estimate of ($0.37). Revenue for the quarter came in at $922 thousand, versus the consensus estimate of $6.06 million.

For earnings history and earnings-related data on Amicus Therapeutics, Inc. (FOLD) click here.

Earnings